Table 4. Intravenous (IV), Oral (PO), and Intraperitoneal (IP) Pharmacokinetic Parameters for 31 in CD-1 Micea.
| route | Cmax (ng/mL) | AUC(0–t) (h·ng/mL) | t1/2 (h) | Clobs (mL/min/kg) | Vss_obs (L/kg) | F (%) |
|---|---|---|---|---|---|---|
| IV 1 mg/kg | 30.8 ± 2.0 | 1.22 ± 0.12 | 508 ± 27 | 33.2 ± 4.1 | ||
| PO 30 mg/kg | 13.9 ± 6.2 | 122 ± 40 | 13.0 ± 4.2 | |||
| IP 30 mg/kg | 83.0 ± 5.9 | 518 ± 96 | 7.52 ± 1.72 |
a
Pharmacokinetic parameters were determined after a single dose administered intravenously (1 mg/kg, n = 3), orally (30 mg/kg, n = 3), or intraperitoneally (30 mg/kg, n = 3). IV compound was formulated in 30% dimethylacetamide (DMA) + 10% polyethylene glycol 200 (PEG200) + 5% Kolliphor ELP in Milli-Q water. PO and IP compounds were formulated in 0.2 M phosphate buffer, pH 6.8.